Hospitals, Market Share, and Consolidation

The Harvard community has made this article openly available. **Please share** how this access benefits you. Your story matters

<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Published Version</td>
<td>doi:10.1001/jama.2013.281675</td>
</tr>
<tr>
<td>Citable link</td>
<td><a href="http://nrs.harvard.edu/urn-3:HUL.InstRepos:32306634">http://nrs.harvard.edu/urn-3:HUL.InstRepos:32306634</a></td>
</tr>
<tr>
<td>Terms of Use</td>
<td>This article was downloaded from Harvard University's DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at <a href="http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA">http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA</a></td>
</tr>
</tbody>
</table>
Special Communication

Hospitals, Market Share, and Consolidation

David M. Cutler, PhD; Fiona Scott Morton, PhD

A large reduction in use of inpatient care combined with the incentives in the Affordable Care Act is leading to significant consolidation in the hospital industry. What was once a set of independent hospitals having arms-length relationships with physicians and clinicians who provide ambulatory care is becoming a small number of locally integrated health systems, generally built around large, prestigious academic medical centers. The typical region in the United States has 3 to 5 consolidated health systems, spanning a wide range of care settings, and a smaller fringe of health care centers outside those systems. Consolidated health systems have advantages and drawbacks. The advantages include the ability to coordinate care across different practitioners and sites of care. Offsetting this is the potential for higher prices resulting from greater market power. Market power increases because it is difficult for insurers to bargain successfully with one of only a few health systems. Antitrust authorities are examining these consolidated systems as they form, but broad conclusions are difficult to draw because typically the creation of a system will generate both benefit and harm and each set of facts will be different. Moreover, the remedies traditionally used (eg, blocking the transaction or requiring that the parties divest assets) by antitrust authorities in cases of net harm are limited. For this reason, local governments may want to introduce new policies that help ensure consumers gain protection in the event of consolidation, such as insurance products that charge consumers more for high-priced clinicians and health care centers, bundling payments to clinicians and health care organizations to eliminate the incentives of big institutions to simply provide more care, and establishing area-specific price or spending targets.

Methods

Analysis of Hospital Markets

Our analysis of hospital markets is based on data from the American Hospital Association (AHA). We used data on nonfederal, short-term general and specialty hospitals that have facilities and services available to the public.

Information on hospital days and the number of hospitals over time was derived from the AHA Chartbook. To understand how hospital markets have become structured, we analyzed information for the 306 hospital referral regions (HRRs) spanning the country, using data from 2010. Hospitals were grouped into systems, with the hospitals in each system treated as an entity. We considered systems only within the same HRR. If a parent system had multiple hospitals in different HRRs, each HRR was considered separately so that we could adequately assess the competitive environment in each HRR.

To characterize the competitive environment in the HRR, we used 2 metrics. First, we considered the share of admissions that are captured by a certain number of institutions (eg, the share of admissions in the largest 3 hospitals or hospital systems). Second, we calculated for each market using the Herfindahl-Hirschman Index (HHI) of concentration. This variable is the sum of the squared market share of each hospital or hospital system in the market multiplied by 10 000. For example, a market with only 1 inpatient institution would have a squared market share equal to 1, and thus an HHI of 10 000. Conversely, a mar-
ket with a large number of small institutions would have a small sum of squared market shares, and thus an HHI near 0. As is standard, we considered markets highly concentrated if they have an HHI greater than 2500, moderately concentrated if they have an HHI between 1500 and 2500, unconcentrated if they have an HHI between 100 and 1500, and highly competitive if they have an HHI below 100.5

Horizontal and Vertical Consolidation

Horizontal consolidation involves hospitals merging with other hospitals. Throughout the article, the term health care provider entity refers to a hospital, outpatient center, physician group, clinic, rehabilitation center, nursing home, home health agency, or any other entity that provides health care to patients and sets or negotiates prices. Vertical consolidation involves hospitals consolidating with other health care provider entities. We used a variety of data sources to assess each. The number of hospitals in systems was from the AHA and included the universe of short-term hospitals (N = 4973). Data on hospital mergers and acquisitions were from Irving Levin Associates and cover the entire market.6 The trend in the HHI was reported by Gaynor7 based on calculations from AHA data.

The number of hospitals owning postacute and other outpatient facilities was from the AHA Chartbook3 and included the full sample of hospitals noted above. Data on ownership of physician practices was from Medical Group Management Association surveys.8

Hospital Bond Ratings

Data on hospital bond ratings were not systematically collected; we instead used data from Moody’s on a sample of hospitals.9 A high-grade bond was defined as a bond rated Aa3 or higher (equivalent to an AA− at Fitch and Standard and Poor’s).10 Such bonds are more likely to be repaid than lesser-rated bonds. The top rating is termed prime and corresponds to a bond rated Aaa at Moody’s (equivalent to an AAA at Fitch and Standard and Poor’s).

Results

Hospital Use

Hospital use and the number of short-term acute hospitals have declined between 1981 and 2011 (Figure 1). During the entire period, hospital days declined by 33% despite a growing and aging population. Coincident with the decline in use, more than 15% of hospitals closed.

Hospital bond ratings reflect the tenuous economic circumstances. Of 494 hospitals with debt rated by Moody’s, only 18% received a high grade; none were rated prime.

Extent of Consolidation

Both horizontal and vertical consolidation has increased in health care. Sixty percent of hospitals are now part of health systems, up 7 percentage points from a decade ago. The average local system has 3.2 independent hospitals. From 2007 to 2012, 432 hospital merger and acquisition deals were announced, involving 835 hospitals.

Expanding vertically, hospitals increasingly own physician practices and health care entities that provide postacute care (Table 1).
From 2004 to 2011, hospital ownership of physician practices increased from 24% of practices to 49%. Postacute care health care organizations and services are also increasingly affiliated with hospitals. Sixty percent of hospitals offer home health services, 37% have skilled nursing facilities, 62% own hospice services, and 15% provide assisted living options.

**Hospital Market Organization**

Across the 306 HRRs, the largest market participant (usually a system) accounted for a mean of 42% of all the hospital inpatient days (median of 38%). In nearly 68% of HRRs, the largest participant was or contained at least 1 academic medical center.

Most HRRs were characterized by multiple large hospitals or hospital systems, although not a large number of such systems (Figure 2). On average, the top 3 share leaders in an area accounted for 77% of hospital admissions, and the top 5 hospitals or systems accounted for 88%. A general characterization of the typical hospital market in the United States is that it has 1 dominant system, 2 to 3 smaller systems, and a residual fringe of smaller institutions.

**Figure 2. Cumulative Market Share Across All Hospital Referral Regions**

<table>
<thead>
<tr>
<th>No. of Hospitals or Hospital Systems per HHR</th>
<th>Cumulative Market Share, %</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>100</td>
</tr>
<tr>
<td>2</td>
<td>80</td>
</tr>
<tr>
<td>3</td>
<td>60</td>
</tr>
<tr>
<td>4</td>
<td>40</td>
</tr>
<tr>
<td>5</td>
<td>20</td>
</tr>
<tr>
<td>6</td>
<td>10</td>
</tr>
<tr>
<td>7</td>
<td>5</td>
</tr>
<tr>
<td>8</td>
<td>2</td>
</tr>
<tr>
<td>9</td>
<td>1</td>
</tr>
<tr>
<td>10</td>
<td>0</td>
</tr>
</tbody>
</table>

All hospitals in the hospital referral region (HRR) belonging to the same system are grouped together as 1 institution. The cumulative market share is based on the number of inpatient days in each facility.

**Hospital Referral Region Concentration Across the United States**

- **A** Hospital referral regions
- **B** Hospital referral regions proportional to the population

The designation of concentration is based on the HHI, with categories of concentration defined by the Department of Justice and Federal Trade Commission. Both maps show that high concentration of hospitals is pervasive across the country. There are no hospital referral regions with a "highly competitive" HHI (<100).

The extent of hospital concentration has increased over time. The hospital HHI has increased by 40% since the mid-1980s, changing from a market with an average 5 independent firms (there were >5 independent hospitals, but approximately 5 major ones) to a market with approximately 3 independent firms.

**Discussion**

The quantity of hospital care demanded has declined over time; inpatient days decreased by one-third between 1981 and 2011. This decline is generally attributed to a few factors. The first factor is technological innovations (eg, minimally invasive surgery) that lessen the need for inpatient care. Economic considerations are also driving reduced hospital use. Hospitals are more expensive than ambulatory surgery centers or outpatient facilities. Thus, patients or insurers with a financial stake in where patients receive care increasingly prefer less intensive settings.

The reduction in demand for hospital care has not affected all institutions the same way. Even as inpatient demand has declined, there is no realistic substitute to the tertiary care hospital for patients needing advanced, technology-driven treatment. The learning curve for individual physicians and surgical teams means that the large hospital in a city or region will frequently offer better care options to patients. As the advanced treatments become ever more sophisticated and expensive, they become increasingly concentrated in fewer inpatient institutions. Furthermore, the research and education focus of many large teaching hospitals may result in their offering more innovative treatments. Large teaching hospitals also have greater endowment and revenue streams than smaller hospitals, making them a valuable source of capital when small hospitals need to invest in the facility, equipment, or information systems.
Thus, flagship academic medical centers offering perceived higher quality care often wield enormous market power. Notwithstanding the observed decline in hospital days used, consumers highly value the option of obtaining care at these hospitals, and thus highly value insurance that allows access to these institutions.12 Furthermore, a patient who has a serious illness and also is well insured will seek out these hospitals with little regard for price. A small hospital with fewer patients may gain financially by joining an academic medical center’s system. The result is pressure for small institutions to combine with large institutions, and even for large institutions to merge with each other. For small hospitals, access to capital is made easier by merging with a large hospital, and payment rates are often higher. For large hospitals, consolidation with small hospitals increases the inpatient base to support their high fixed costs. Consolidation with other large hospitals can allow the new entity to negotiate higher prices with insurers, who would otherwise play large institutions against each other.

Upcoming policy changes seem likely to further reinforce the pressure to consolidate. The Affordable Care Act (ACA) reduced the growth of Medicare hospital reimbursement by about 1.5 percent points annually, the latest in a series of payment reductions stretching back many years.13 Cash-strapped state governments have reduced fees to inpatient institutions. The presumed revenue enhancement from expanded insurance coverage may not occur if states choose not to adopt the ACA Medicaid offer; 26 states have stayed out initially.14 These financial challenges will make it even more difficult for weaker hospitals to survive on their own.

Potential Benefits and Harms of Consolidation for Consumers

Large health systems may create benefits as well as harms (Table 2). On the benefit side, large health systems may be able to provide higher quality care. Studies have shown a clear relationship between volume and outcome for many surgical procedures.15,16 Consolidation can increase volume for specialized services and thus improve quality. Similarly, larger systems are able to spread the financial burden of high-cost investments (eg, electronic medical records; EMRs) better across their constituent members.

Consolidation may also contribute to cost savings. Indeed, this is the rationale for accountable care organizations (ACOs). Care provision may be made more efficient if one parent health organization group oversees and controls the continuum of care. For example, different practitioners and health centers with a shared medical record may find it easier to reduce duplication and plan across settings. Additionally, the institution as a whole may consider care across settings to make it more efficient (eg, a home visit from a nurse as part of rehabilitation may prevent another hospital admission or an expensive drug may prevent an even more expensive hospital admission). For this reason, many of the least resource-intensive health centers in the country are integrated care organizations.17

Empirical studies on cost savings from consolidation are mixed.18,19 Although some studies show cost savings after a consolidation, such savings require significant integration of different parts of the health system, which does not always occur. Thus, this rationale for consolidation remains important theoretically but tentative, and likely complex, empirically.

One of the challenges of hospital consolidation is concern about increasing prices. For instance, consider a prototypical marketplace that once had 15 independent hospitals, roughly the average number in a market in 2010. If an insurer wanted most, but not all, hospitals in its network, it could rationally bargain over price with the hospitals in the area and be willing not to come to an agreement with a few hospitals asking for very high prices. Even though some consumers may object to the omission of those hospitals from the insurer’s network, most patients would be able to find a substitute hospital somewhere in the large set of choices offered in the network.

In contrast, if the hospitals consolidate into only 3 large systems, insurers will find it difficult to exclude even 1 system from the plan because that would mean many hospitals would be excluded from the network, with at least 1 likely being a major medical center. Consumers (and employers) may not want to purchase a plan that excludes such a large part of the market. Thus, with no system plausibly able to be excluded from the insurer’s network, each system can charge insurers a higher price. These price increases affect consumers directly in their out-of-pocket payments when they buy insurance and when they pay taxes that fund public insurance programs.

Nonprofit hospitals traditionally argue that consolidation is reasonable because their nonprofit status means they will not increase prices. In contrast, the data demonstrate that ownership status is not a deterrent to price increases, and prices are just as high in nonprofit as in for-profit organizations.20 Nonprofit hospitals appear to share the goal of maximizing profit; they simply distribute the profits in a different way by providing unprofitable services, supporting research, underwriting free care, and building up reserves (instead of distributing profits to shareholders).

Consistent with the theory, the recent wave of hospital consolidation has led to price increases for hospital care. A recent summary of
cites 8 studies that show price increases in the range of 10% to 40% due to mergers. Similarly, the attorney general of Massachusetts has shown that prices for medical services vary substantially across hospitals and other health care centers, with little relationship between quality and price but a strong relationship between institutional reputation and price. 21 Another potential adverse effect of consolidation is lack of innovation in products and processes. With respect to product innovation, most studies find that investment in new technologies is positively correlated with profits. 22 Process innovations, however, seem to decline with market power consolidated in a few institutions. Organizations with market power often lack the incentive to develop simple items such as checklists and uniform protocols that deliver services in newer, more efficient ways. 23 Such changes are difficult, and managers of large, profitable organizations might conclude that they do not need to undertake them.

Antitrust Concerns

The degree of consolidation induced by recent mergers is significant enough to warrant antitrust scrutiny. The attempted merger in 2011 of AT&T and T-Mobile provides a helpful benchmark; the proposed merger would have placed 96 of the top 100 markets into the highly concentrated category, which was one of the reasons it was blocked by the Department of Justice. 24 Health care is not as concentrated as cellular telephone service would have been, but many markets are in the noncompetitive range.

In considering the response of antitrust authorities to transactions in the health care sector, a fundamental distinction needs to be made between the effects of consolidation on public and private payers. Public payers (such as Medicare and Medicaid) set prices and do not negotiate with hospitals and other health care organizations. Because of their large patient volume, essentially all hospitals accept Medicare and Medicaid rates. Thus, if large health care organizations become more efficient and lower treatment costs, public payers can readily leverage these savings by reducing the amount they reimburse. The reductions in hospital update factors (by about 1.5 percentage points annually) in the ACA are an example of how this could play out.

Private payers, in contrast, need to negotiate reimbursement rates with health care organizations. With less negotiating leverage as a result of consolidation, private insurers may find it more difficult to leverage cost savings into reduced reimbursement for the health care organization. An integrated health system may reduce costs by 10% to 20%, but it is uncertain whether doing so will translate into lower charges to private insurers.

For this reason, antitrust agencies are paying increasing attention to the possible effect of consolidation on private payers. The Justice Department and Federal Trade Commission recently issued guidance on what transactions would fall into a safe harbor as hospitals transform into ACOs (Figure 4). 25 Consolidation will be in the safety zone if the consolidating parties have fewer than 30% of the market in their relevant service area and are not exclusive health care provider entities to some ACOs, if they are larger but there are no other ACOs in the area and they are not exclusive to the ACO, or if they are in rural areas in which consolidation will necessarily be high. The antitrust authorities have been supported by the courts; a recent US Supreme Court decision gave the Federal Trade Commission greater ability to police hospital mergers. 26 Antitrust analysis involves several principles. An important principle is that the antitrust law exists to protect competition, not particular competitors. The sole question for antitrust agencies in considering whether health systems would become too large with a
particular consolidation is whether consumers will be better or worse off as a result. The financial status of any health care organization is immaterial, except insofar as it affects consumer welfare.

A second important antitrust principle is that all effects of a transaction must be analyzed and balanced to determine the net effect on consumers. In a situation in which consumers are helped by some aspects of a consolidation and harmed by others, the decision about whether the consolidation should be permitted should be based on whether the benefits significantly outweigh the harms. Thus, simply demonstrating that clinicians and health care provider entities have increased access to a common EMR in a large system, for example, will not outweigh the harm from higher prices unless the EMR is being used to create a large enough consumer benefit.

Third, a baseline criterion for evaluating efficiencies from a consolidation is whether those efficiencies could be achieved in ways that do not lessen competition. For instance, although there may be benefits of harmonizing EMRs, can those benefits be achieved by a simple contract or a clinical affiliation rather than a merger? If yes, the agencies will not look favorably on arguments that increased market power due to the merger of large institutions is justified.

The level of benefits and harms in a given situation is likely to vary based on the size of the community. In large metropolitan areas, economies of scale and vertical integration may be achievable in a large system that is not dominant because the market is so large. The agencies will likely be skeptical of the need for extreme consolidation in such an area.

In smaller communities, efficiency gains of the same type may require consolidation that includes hospitals and other health care organizations comprising a larger fraction of the market. Such consolidation could cause large price increases. In that case, the balancing test of the agencies will be more difficult. For example, does the increase in quality of care offset the higher prices? Determining the best outcome in such a situation will require careful analysis.

Possible Remedies
Striking the right balance in health care will be difficult. Consolidation has many possible advantages but also many potential disadvantages.

To the extent that some intervention in health care markets is appropriate, traditional antitrust enforcement focuses on blocking the proposed merger or on divestiture of the hospital, physician group, or other entity that is generating the competitive concerns. The US Department of Justice and the Federal Trade Commission may also use what are termed conduct remedies, which are not structural in nature, but rather behavioral. An example of this type of remedy is a restriction on the type of contracts into which the combined firm may enter. The agencies tend not to accept remedies of the form in which the combined firm promises not to raise prices because these would be difficult to enforce and therefore unlikely to work, and would also involve expensive monitoring by agency personnel.

Given the limited options available by using antitrust enforcement, state and federal health care agencies may choose to pursue other avenues to enhance the benefits of consolidation relative to the costs. The following 3 avenues may be appropriate.

Insurance Changes
A first direction is to encourage more selective contracting between insurers and health systems than simply inclusion or exclusion of a system from a network. Even though all health systems may need to be in an insurer’s network, they do not need to have the same cost sharing for consumers. Thus, routine surgery could involve higher consumer cost sharing if provided at the dominant health system in a market than in a less expensive one. This policy is termed a tiered network, analogous to the tiering of pharmaceuticals in a formula. This is already common in numerous health care plans.

Dominant institutions are likely to oppose this development because they price routine care at rates above cost, and therefore tiering threatens their revenue model. It is likely that dominant hospitals will prefer insurers to cover all their services at the same cost sharing, even though this may raise the total cost of care. If policy wishes to circumvent this, it may need to prohibit health care provider entities from insisting on these provisions (eg, by prohibiting the contract requirement that all services be covered on an even basis).

Bundled Payments
A second direction for policy is to change the incentives for health systems to ones that strongly encourage cost savings, not just the provision of profitable interventions. Dominant systems are profitable in part because they provide well-reimbursed procedures at very high rates. Reducing the profits from these procedures can limit the money to be made through excessive procedures, thus reducing the dominant system’s market power.

The future of the ACA is critical here. Some of the consolidation in hospital care has been driven by the promise of reforms in the ACA that would reduce the gains resulting solely from providing more intensive care. Indeed, this was the basis of the ACO program. Having fostered consolidation as a strategy for increased efficiency, it is incumbent upon the Centers for Medicare & Medicaid Services to follow through with rapid transition into alternative payment mechanisms. Similarly, private insurers will need to follow the ACA lead, as many are starting to do. For example, Arkansas state legislation requires episode-based payment by Medicaid and private insurers for a small but increasing number of conditions.

Price or Spending Targets
A third approach, if there is no other way to obtain good care except through monopoly organizations, is for policy makers to regulate prices or total spending. Price regulation of natural monoplies has a long history in the United States, and Medicare and Medicaid have used administrative prices for many years. Price regulation could expand to private insurers (eg, by requiring dominant ACOs to sell their subspecialized services to every insurer or other ACOs at reasonable rates).

A substitute for price regulation is setting overall expenditure targets. Oregon has started such a policy in its Medicaid program. In exchange for additional federal funds, Oregon agreed to reduce the per capita medical trend by 2 percentage points. In turn, Oregon has organized Medicaid health care provider entities into coordinated care organizations capable of accepting bundled rates increasing at a low rate.

A different approach is being pioneered in Massachusetts, which has set an overall expenditure growth target for medical care as a whole. The target is for overall costs (both public and private) to increase at the rate of the state economy or slightly below it. Unlike in Oregon, the penalties for nonadherence to the target are not fully specified in law. Even still, the legislation is a significant model.
Conclusion

A central economic question about the emerging health system is whether consolidation of large hospital institutions is beneficial or harmful. The answer is not always the same because it depends on the environment in which consolidation occurs, who is consolidating, how large each organization is in its different markets, and whether the combined entity improves quality of care. Having policy makers be smart about how hospitals and other health care institutions are allowed to consolidate is critical to ensuring that the population is receiving the best care possible at reasonable, affordable prices.

ARTICLE INFORMATION

Author Contributions: Dr Cutler had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. The order of the authors is alphabetical and both authors contributed equally. Study concept and design: Cutler, Scott Morton. Acquisition of data: Cutler, Scott Morton. Analysis and interpretation of data: Scott Morton. Drafting of the manuscript: Cutler, Scott Morton. Critical revision of the manuscript for important intellectual content: Cutler, Scott Morton. Statistical analysis: Cutler, Scott Morton. Administrative, technical, or material support: Cutler, Scott Morton. Study supervision: Scott Morton.

Conflict of Interest Disclosures: The authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Cutler reported receiving institutional grant support from the National Institutes of Health; and honoraria, reimbursement for travel expenses, speaking fees, and reimbursement for parking from several universities, associations, organizations, and companies. Dr Scott Morton reported serving as a general antitrust consultant to and providing general antitrust testimony for Charles River Associates; and being employed by the US Department of Justice.

REFERENCES